

# POCT Series Inflammation Diagnostic Reagents



**Make Medical Test More Accurate**

---

Guangzhou Labsim Medical Diagnostics Co., Ltd

# Reagent | Inflammation Diagnostic Reagents

Test Item	Sample	Reaction Time	Linearity Range	Extensible Range	Reference	Certification
<b>CRP</b> SA.02.00002 (SEMI) SJ.02.00002 (AUTO)	Serum / Plasma / Whole blood	3 min	0.5-200 mg/L	0.01-240 mg/L	< 10 mg/L	CE NMPA
Anticipated Use / Clinical Significance: 1. Differential diagnosis of bacterial infection or viral infection: CRP is significantly increased in bacterial infection, while most of them are normal or slightly increased in viral infection, and the increase in CRP is positively correlated with the degree of bacterial infection. 2. Predict the prognosis and recurrence of infectious diseases. 3. To evaluate the efficacy of antimicrobial therapy.						
<b>CRP</b> ( Disposable sampling head ) SA.02.00115 (SEMI)	Serum / Plasma / Whole blood / Peripheral blood	5 min	0.5-200 mg/L	0.01-240 mg/L	< 10 mg/L	CE
Anticipated Use / Clinical Significance: CRP is a non-specific inflammatory marker that directly participates in inflammation and cardiovascular diseases such as atherosclerosis. It is the most powerful predictor and risk factor for cardiovascular diseases. This product is used for the quantitative determination of C-reactive protein (CRP) content in human peripheral blood, serum, plasma, and whole blood.						
<b>PCT</b> SA.02.00004 (SEMI) SJ.02.00004 (AUTO)	Serum / Plasma / Whole blood	15 min	0.1-100 ng/mL	0.01-120 ng/mL	< 0.5 ng/mL	CE NMPA
Anticipated Use / Clinical Significance: 1. It is used for the differential diagnosis of bacterial infection or viral infection. 2. It is used for the diagnosis of sepsis, severe sepsis and septic shock. 3. It is used to assess the severity of sepsis syndrome and systemic inflammatory response. 4. For disease progression and prognostic significance. 5. Guidance for antibiotic therapy.						
<b>SAA</b> SA.02.00005 (SEMI) SJ.02.00005 (AUTO)	serum / plasma / whole blood	15 min	2.0-100 mg/mL	0.01-300 mg/mL	< 10 mg/mL	CE FDA NMPA
Anticipated Use / Clinical Significance: 1. It is used to detect viral and bacterial infections in infectious diseases. 2. Applied to the diagnosis of cardiovascular diseases. 3. It is used in transplant rejection.						
<b>IL-6</b> SA.02.00006 (SEMI) SJ.02.00006 (AUTO)	serum / plasma / whole blood	15 min	3.0-4000 pg/mL	0.01-4800 pg/mL	< 7.5 pg/mL	CE NMPA
Anticipated Use / Clinical Significance: 1. Differential diagnosis of early markers of acute inflammation. 2. Assessment of infection severity and prognosis. 3. Diagnosis of sepsis. 4. Early warning and diagnostic indicators of sepsis.						
<b>CRP / SAA</b> SA.02.00007 (SEMI) SJ.02.00007 (AUTO)	Serum / Plasma / Whole blood	15 min	CRP: 0.5-150 mg/L SAA: 0.5-300 mg/L	CRP: 0.01-240 mg/L SAA: 0.01-300 mg/L	CRP < 8.28 mg/L SAA < 10 mg/L	CE NMPA
Anticipated Use / Clinical Significance: 1. Early inflammatory markers of infectious diseases. 2. Distinguish local bacterial and viral infections. 3. Comprehensively reflect the severity of infectious diseases (including bacteria and viruses). 4. Comprehensive prognostic assessment of infectious diseases (including bacteria and viruses). 5. Coronary heart disease risk prediction indicators and other clinical applications.						
<b>PCT / IL-6</b> SA.02.00008 (SEMI) SJ.02.00008 (AUTO)	Serum / Plasma / Whole blood	15 min	IL-6: 10-1000 pg/mL PCT: 0.1-40 ng/mL	IL-6: 0.01-4800 pg/mL PCT: 0.01-120 ng/mL	IL-6 < 15 pg/mL PCT < 0.5 ng/mL	CE NMPA
Anticipated Use / Clinical Significance: 1. Improve the diagnostic performance of infection and sepsis, making it earlier and more specific. 2. Assist in the differential diagnosis of Gram-positive or Gram-negative bacterial infections. 3. Provide earlier warning of infection. 4. Guide the rational use of antibiotics. 5. Diagnosis and prognosis assessment of other diseases.						
<b>HBP / PCT</b> SA.02.00053 (SEMI) SJ.02.00053 (AUTO)	Plasma	15 min	HBP: 1-200 ng/mL PCT: 0.05-50 ng/mL	HBP: 0.1-300 ng/mL PCT: 0.01-120 ng/mL	HBP < 15 ng/mL PCT < 0.5 ng/mL	CE
Anticipated Use / Clinical Significance: 1. Used for the differential diagnosis of bacterial infection or viral infection. 2. Used for the early diagnosis, severity and prognosis assessment of sepsis and septicemia. 3. The combined detection of HBP and PCT can effectively distinguish local or systemic infection and effectively monitor the entire process of infection.						
<b>HBP</b> SA.02.00054 (SEMI) SJ.02.00054 (AUTO)	Plasma	15 min	5-300 ng/mL	0.1-300 ng/mL	< 15 ng/mL	CE
Anticipated Use / Clinical Significance: 1. HBP as a diagnostic indicator of local infection: HBP levels in cerebrospinal fluid can improve the accuracy of distinguishing bacterial and viral nervous system infections. 2. HBP assists in the diagnosis of urinary tract infection. 3. HBP predicts the occurrence of septic shock. 4. HBP predicts circulatory failure in sepsis: HBP is currently clinically used as a marker of severe sepsis.						
<b>HNL</b> SA.02.00108 (SEMI)	Serum	/	/	/	/	/
Anticipated Use / Clinical Significance: This product is used for quantitative in vitro detection of the content of neutrophil apolipoprotein (HNL) in human serum. It is clinically used for auxiliary diagnosis of bacterial infections; During bacterial infections, the peak level of HNL in serum increases rapidly within a short period of time. However, in healthy individuals or those with viral infections, the content of HNL does not show significant increase. The HNL protein in renal tubular epithelial cells can be released within 2 hours after renal injury occurs, causing a significant increase in HNL levels in urine. Therefore, it can be used for early diagnosis of renal function damage.						

# Instrument | POCT Analyzers

Instrument Name	Model	Picture	Certification
Handheld Fluorescence Immunoassay Analyzer	AFS330H		CE NMPA
Fluorescent Immunoanalyzer	AFS800		CE NMPA
Fluorescent Immunoanalyzer	AFS-1000		CE FDA NMPA
Immunofluorescence Analyzer	L300		CE NMPA
Multichannel Fluorescent Immunoanalyzer	AFS2100S		CE FDA NMPA
Immunofluorescence Analyzer	AFS2600B		CE FDA NMPA
Fluorescence Immunoassay Analyzer	AFS3000		CE FDA NMPA



NMPA



## Guangzhou Labsim Medical Diagnostics Co., Ltd.

📍 Room 301, Building H7, No. 39 Ruihe Road, Huangpu District, 510700 Guangzhou City, Guangdong Province, PEOPLE'S REPUBLIC OF CHINA

☎ Tel: +86-20-28200186

📠 Fax: +86-20-28200183

✉ Email: [info@labsim-ivd.com](mailto:info@labsim-ivd.com)

🌐 Web: [www.labsim-ivd.com](http://www.labsim-ivd.com)

